UK-based Oxford Nanopore Technologies Ltd has raised £100 million in a private share placement to support the commercial development of its new hand-held device for sequencing whole human genomes at a fraction of the cost of earlier technologies. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
